B55β-Associated PP2A Complex Controls PDK1-Directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer

Cancer Cell

Volumn 18, Issue 5, 2010, Pages 459-471

  Tan, Jing ^a,b   Lee, Puay Leng ^a   Li, Zhimei ^a   Jiang, Xia ^a   Lim, Yaw Chyn ^b   Hooi, Shing Chuan ^b   Yu, Qiang ^a,b,c  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; DOXYCYCLINE; MYC PROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN SERINE THREONINE KINASE; PROTEIN SUBUNIT; RAPAMYCIN; RAPAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; CANCER INHIBITION; COLORECTAL CANCER; COMPLEX FORMATION; DNA METHYLATION; DRUG SENSITIVITY; EMBRYO; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 78249287240     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.10.021     Document Type: Article

References (54)

1. Andrabi S., Gjoerup O.V., Kean J.A., Roberts T.M., Schaffhausen B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc. Natl. Acad. Sci. USA 2007, 104:19011-19016.
2. Arnold H.K., Sears R.C. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol. Cell. Biol. 2006, 26:2832-2844.
3. Arnold H.K., Sears R.C. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008, 27:147-158.
4. Calin G.A., di Iasio M.G., Caprini E., Vorechovsky I., Natali P.G., Sozzi G., Croce C.M., Barbanti-Brodano G., Russo G., Negrini M. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19:1191-1195.
5. Chen W., Possemato R., Campbell K.T., Plattner C.A., Pallas D.C., Hahn W.C. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004, 5:127-136.
6. Chen W., Arroyo J.D., Timmons J.C., Possemato R., Hahn W.C. Cancer-associated PP2A Alpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005, 65:8183-8192.
7. Easton J.B., Houghton P.J. mTOR and cancer therapy. Oncogene 2006, 25:6436-6446.
8. Eichhorn P.J., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795:1-15.
9. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
10. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9:341-349.
11. Feldman R.I., Wu J.M., Polokoff M.A., Kochanny M.J., Dinter H., Zhu D., Biroc S.L., Alicke B., Bryant J., Yuan S., et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 2005, 280:19867-19874.
12. Granville C.A., Memmott R.M., Gills J.J., Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 2006, 12:679-689.
13. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
14. Hahn W.C., Dessain S.K., Brooks M.W., King J.E., Elenbaas B., Sabatini D.M., DeCaprio J.A., Weinberg R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 2002, 22:2111-2123.
15. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356:2271-2281.
16. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353:417-439.
17. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
18. Jiang X., Tan J., Li J., Kivimae S., Yang X., Zhuang L., Lee P.L., Chan M.T., Stanton L.W., Liu E.T., et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008, 13:529-541.
19. Junttila M.R., Puustinen P., Niemela M., Ahola R., Arnold H., Bottzauw T., Ala-aho R., Nielsen C., Ivaska J., Taya Y., et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62.
20. Kikani C.K., Dong L.Q., Liu F. "New" -clear functions of PDK1: beyond a master kinase in the cytosol?. J. Cell. Biochem. 2005, 96:1157-1162.
21. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
22. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
23. Kuo Y.C., Huang K.Y., Yang C.H., Yang Y.S., Lee W.Y., Chiang C.W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283:1882-1892.
24. Lim M.A., Kikani C.K., Wick M.J., Dong L.Q. Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc. Natl. Acad. Sci. USA 2003, 100:14006-14011.
25. Mao J.H., Kim I.J., Wu D., Climent J., Kang H.C., DelRosario R., Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321:1499-1502.
26. Maurer M., Su T., Saal L.H., Koujak S., Hopkins B.D., Barkley C.R., Wu J., Nandula S., Dutta B., Xie Y., et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 2009, 69:6299-6306.
27. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colorectal cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
28. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
29. Padmanabhan S., Mukhopadhyay A., Narasimhan S.D., Tesz G., Czech M.P., Tissenbaum H.A. A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell 2009, 136:939-951.
30. Peifer C., Alessi D.R. Small-molecule inhibitors of PDK1. ChemMedChem 2008, 3:1810-1838.
31. Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc. Natl. Acad. Sci. USA 1999, 96:4438-4442.
32. Rangarajan A., Hong S.J., Gifford A., Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183.
33. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
34. Ruediger R., Pham H.T., Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001, 20:1892-1899.
35. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
36. Sablina A.A., Chen W., Arroyo J.D., Corral L., Hector M., Bulmer S.E., DeCaprio J.A., Hahn W.C. The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 2007, 129:969-982.
37. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., Vass J.K., Athineos D., Clevers H., Clarke A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679.
38. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
39. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
40. Scott K.L., Kabbarah O., Liang M.C., Ivanova E., Anagnostou V., Wu J., Dhakal S., Wu M., Chen S., Feinberg T., et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009, 459:1085-1090.
41. Seeling J.M., Miller J.R., Gil R., Moon R.T., White R., Virshup D.M. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999, 283:2089-2091.
42. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000, 60:3504-3513.
43. Sontag E., Fedorov S., Kamibayashi C., Robbins D., Cobb M., Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993, 75:887-897.
44. Su Y., Fu C., Ishikawa S., Stella A., Kojima M., Shitoh K., Schreiber E.M., Day B.W., Liu B. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol. Cell 2008, 32:652-661.
45. Takagi Y., Futamura M., Yamaguchi K., Aoki S., Takahashi T., Saji S. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000, 47:268-271.
46. Tamaki M., Goi T., Hirono Y., Katayama K., Yamaguchi A. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol. Rep. 2004, 11:655-659.
47. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12:122-127.
48. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., Hennessy B.T., Tseng H., Pochanard P., Kim S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
49. Virshup D.M., Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol. Cell 2009, 33:537-545.
50. Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J., Evans G.A. Alterations of the PPP2R1B gene in human lung and colorectal cancer. Science 1998, 282:284-287.
51. Westermarck J., Hahn W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 2008, 14:152-160.
52. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W.C., Stukenberg P.T., Shenolikar S., Uchida T., et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004, 6:308-318.
53. Zhao J.J., Gjoerup O.V., Subramanian R.R., Cheng Y., Chen W., Roberts T.M., Hahn W.C. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003, 3:483-495.
54. Zhao J.J., Cheng H., Jia S., Wang L., Gjoerup O.V., Mikami A., Roberts T.M. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl. Acad. Sci. USA 2006, 103:16296-16300.